Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341500 | 0.85 | MLYCD (0.42) | MLYCDROCK2MAPK14HSP90AA1 | |
| SCHEMBL4335490 | 0.84 | MAPK14 (0.59) | MLYCDROCK2MAPK14HSP90AA1CTSA | |
| SCHEMBL4346675 | 0.83 | MAPK14 (0.45) | MLYCDROCK2MAPK14HSP90AA1ALDH1A1 | |
| SCHEMBL4337504 | 0.83 | MAPK14 (0.58) | MLYCDROCK2MAPK14HSP90AA1CTSA | |
| SCHEMBL4332757 | 0.82 | MAPK14 (0.52) | MLYCDROCK2MAPK14HSP90AA1CTSA | |
| SCHEMBL4336216 | 0.81 | MAPK14 (0.59) | ROCK2MAPK14HSP90AA1ALDH1A1MAPT | |
| SCHEMBL4330151 | 0.81 | HSP90AA1 (0.55) | MLYCDMAPK14HSP90AA1 | |
| SCHEMBL4339271 | 0.80 | MAPK14 (0.52) | MAPK14HSP90AA1ALDH1A1MAPT | |
| SCHEMBL4340366 | 0.80 | MLYCD (0.44) | MLYCDMAPK14HSP90AA1MAPTCTSA | |
| SCHEMBL4348725 | 0.79 | MAPK14 (0.50) | MLYCDMAPK14HSP90AA1MAPTCTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036905-B1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-8207203-B2 | Pyridylisoxazole derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20090306145-A1 | Pyridylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2036905-A1 | PYRIDYLISOXAZOLE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306145-A1 | Pyridylisoxazole Derivatives | CNKSR1, MAPK1, MAPK3 | MLYCD 4475/4885ROCK2 317/4885MAPK14 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.